Moderna’s JN.1-Adapted COVID-19 Vaccine Approved by MHRA for Adults and Children

Introduction

The MHRA has authorized Moderna’s JN.1-adapted COVID-19 booster vaccine, making it the second bivalent vaccine to be approved in the UK. The vaccine is intended to provide broader protection against the original COVID-19 strain and the Omicron subvariants, including BA.4 and BA.5.

Efficacy and Safety

Efficacy

The JN.1-adapted vaccine has been shown to induce a strong immune response against both the original COVID-19 strain and the Omicron subvariants. In clinical trials, the vaccine produced significantly higher levels of neutralizing antibodies against these variants compared to the original Moderna vaccine.

Safety

The JN.1-adapted vaccine has been found to be safe and well-tolerated in clinical trials. The most common side effects were mild and included pain at the injection site, fatigue, chills, and headache. These side effects typically resolved within a few days.

Eligibility and Administration

Eligibility

The JN.1-adapted vaccine is authorized for use in adults and children aged 6 years and older. It is recommended as a booster dose for those who have completed their primary COVID-19 vaccination series.

Administration

The JN.1-adapted vaccine is administered as a single intramuscular injection in the upper arm. It is recommended to receive this booster dose at least 6 months after the last dose of COVID-19 vaccine.

Benefits of the JN.1-Adapted Vaccine

The JN.1-adapted vaccine offers several benefits, including: * Enhanced protection against the Omicron subvariants, which currently account for the majority of circulating COVID-19 cases * Reduced risk of severe disease, hospitalization, and death from COVID-19 * Broader immunity against a wider range of COVID-19 variants * Contribution to herd immunity and the overall protection of public health

Conclusion

The MHRA’s approval of Moderna’s JN.1-adapted COVID-19 vaccine is a significant step in the fight against the pandemic. This vaccine offers enhanced protection against the Omicron subvariants, providing additional peace of mind and contributing to the overall health and safety of the public.